Epsilogen Announces Acquisition of TigaTx, Inc. to Create Pan-Isotype Cancer Antibody Company April 16, 2025
Solu Therapeutics Closes $41M Series A Financing; First Patient Dosed in Ph 1 Trial of STX-0712 in Patients with CMML and Other Heme Malignancies April 16, 2025
Ph 3 AdvanTIG-302 trial unlikely to meet primary endpoint; Ociperlimab (BGB-A1217) Program to be discontinued April 16, 2025
Ph 3 DeLLphi-304 trial of IMDELLTRA (tarlatamab-dlle) in SCLC patients met primary endpoint at a planned interim analysis April 16, 2025
NDA submitted to the US FDA for ziftomenib in adult patients with R/R AML with NPM 1 mutation April 16, 2025
US FDA Grants Full Approval of VITRAKVI (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors April 16, 2025
